The Trump administration continues to apply rhetorical pressure on the pharmaceutical industry to cut drug prices with both the President (regarding Pfizer) and HHS Secretary Azar flagging that “change is coming”. Supply chain data suggests there has been some success already with the average import value per gram (AIVG) for all pharmaceutical imports to the U.S. having fallen by 29% on a year earlier in May. That’s included oncology / immunotherapy (the largest class) where there was a 32% decline in May, resulting in a 2% retreat from the 12 month trailing average which reached a recor...